- CONTACT US
- AFS
- Business
- Bussiness
- Car
- Career
- Celebrity
- Digital Products
- Education
- Entertainment
- Fashion
- Film
- Food
- Fun
- Games
- General Health
- Health
- Health Awareness
- Healthy
- Healthy Lifestyle
- History Facts
- Household Appliances
- Internet
- Investment
- Law
- Lifestyle
- Loans&Mortgages
- Luxury Life Style
- movie
- Music
- Nature
- News
- Opinion
- Pet
- Plant
- Politics
- Recommends
- Science
- Self-care
- services
- Smart Phone
- Sports
- Style
- Technology
- tire
- Travel
- US
- World
Dec 9 (Reuters) - CVS Health (CVS) on Tuesday forecast 2026 profit above Wall Street estimates and this year's projected earnings, signalling steady progress in the health conglomerate's turnaround plan.
CVS stock rose 5% in early trading on Tuesday.
The company in October projected double-digit earnings growth for 2026 after raising its 2025 profit forecast for the third time.
"We are closing out 2025 with meaningful momentum across our businesses and we expect another year of strong earnings growth in 2026," said Chief Financial Officer Brian Newman on Tuesday.
The company forecast 2026 adjusted profit to be in the range of $7.00 to $7.20 per share, compared with analysts' average estimate of $7.16, according to data compiled by LSEG.
It, however, expects total revenue of at least $400 billion next year, below analysts' average estimate of $419.26 billion.
CVS also raised its 2025 adjusted profit forecast to $6.60 to $6.70 per share from $6.55 to $6.65 previously.
(Reporting by Sneha S K in Bengaluru; Editing by Shinjini Ganguli)
LATEST POSTS
- 1
Let them eat (Taylor Swift) cake: The baker turning A-listers into life-size desserts - 2King Charles shares cancer treatment update, says it's a 'personal blessing'
- 3Early diagnosis leads King Charles to scale back cancer treatment in the new year
- 4Mont Blanc road tunnel reopens to traffic after 15 weeks of repairs
- 5Bavarian leader questions Germany's Eurovision participation
- AstraZeneca to invest $2 billion as part of US manufacturing push
- Analysis-From 'Icarus bug' to flawed panels: Airbus counts cost of relying on single model
- FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths
- Emergent Cold LatAm opens state-of-the-art cold storage hub in Guadalajara
- US FDA panel to weigh bid to market nicotine pouches as lower-risk than cigarettes
- Merck sees over $5 billion opportunity in Cidara's experimental flu drug
- China's 1st reusable rocket explodes in dramatic fireball during landing after reaching orbit on debut flight
- US FDA approves Kura-Kyowa's blood cancer therapy
- Wizz CEO: We’re going to invest $1 b. in Israeli market
